Women's tour mandates gene test for eligibility

The Women’s Tennis Association (WTA) has announced a new policy requiring all players to undergo a one-time genetic test to confirm their biological sex, effective starting in 2026. The test will screen for the presence of the SRY gene, which determines whether an individual is biologically male or female. This change comes as the WTA updates its eligibility rules, aiming to ensure fairness in competition among female athletes. Under the revised policy, players must submit either a cheek swab or blood sample to determine their SRY status. The requirement applies to all participants in WTA tournaments, marking a shift from the previous rule that allowed transgender women to compete if they declared themselves female and maintained low testosterone levels for two years prior to entering competitions. At present, there are no known transgender women actively competing at any level within professional tennis. The WTA stated that the testing process will be conducted with strict adherence to confidentiality and data privacy measures. It also plans to implement a comprehensive player engagement program alongside the introduction of the new policy. “Player screening will begin in 2026,” a WTA spokesperson told Reuters, emphasizing the organization’s commitment to handling the issue with respect and thoughtfulness. This decision follows broader trends in international sports, where several federations have introduced similar genetic testing requirements. In March, the International Olympic Committee (IOC) announced that only biological female athletes, verified through a one-time test, would be eligible to compete in female categories at the Olympics. Similarly, organizations such as World Athletics and World Boxing have adopted comparable policies in recent years. Renee Richards, a former transgender athlete who played on the women’s professional tour from 1977 to 1981, is often cited in discussions around transgender participation in sports. She was coached by Martina Navratilova, a legendary figure in tennis and a vocal opponent of transgender inclusion. Navratilova, an 18-time Grand Slam singles champion, has consistently expressed concerns over the potential advantages transgender athletes might hold due to past male puberty. Aryna Sabalenka, the world number one in women’s tennis, echoed these sentiments in 2023, stating that it would be unfair for women to compete against transgender players. Meanwhile, Billie Jean King, another iconic figure in tennis history, has taken a different stance, viewing the exclusion of transgender athletes as discriminatory. King famously won the original "Battle of the Sexes" match in 1973, challenging traditional gender norms in sports. Transgender advocacy groups argue that excluding transgender athletes constitutes discrimination, emphasizing that individuals should be able to compete based on their self-identified gender rather than biological factors. They also highlight that transitioning does not fully eliminate the physical advantages gained during male puberty, which critics claim persist even after hormone therapy. As the WTA moves forward with its new policy, the debate over transgender inclusion in sports continues to evolve. With other major sporting bodies already enforcing genetic testing requirements, the pressure on tennis to align with these standards appears inevitable. The implementation of the SRY gene test marks a significant step in shaping the future of competitive women’s tennis.